Regentis Biomaterials

Company Overview

Snapshot

Founded in September 2004 by Prof. Dror Seliktar, Regentis Biomaterials operates with 1–10 employees. The company has raised a total of $43.5 million across four funding rounds from eight investors. Regentis Biomaterials became public on NASDAQ in September 2025.

Business overview

Regentis Biomaterials is a tissue-repair company focused on developing and commercializing a hydrogel platform for regenerating damaged tissue. Its primary efforts are directed towards orthopedic treatments, utilizing degradable hydrogel implants. The company's flagship product, GelrinC, is a cell-free, off-the-shelf hydrogel implant designed for treating painful injuries to articular knee cartilage, acting as a scaffold for new cartilage growth. Regentis Biomaterials operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Pharma & Medical Biotechnology, serving the healthcare industry.

Strategic signal

Regentis Biomaterials is accelerating its commercial launch preparations for GelrinC in Europe, with plans to commence surgeon training in June 2026. This indicates a significant step towards market penetration and commercialization of its regenerative implant technology, signaling to investors a strong focus on expanding its global footprint and driving revenue growth in the near term.

Company Intelligence Q&A

What is the primary focus of Regentis Biomaterials' product development?

Regentis Biomaterials primarily focuses on developing and commercializing a hydrogel platform for the repair of damaged tissue, with current efforts concentrated on orthopedic treatments using degradable hydrogel implants to regenerate damaged or diseased tissue.

What is GelrinC and how does it function?

GelrinC is Regentis Biomaterials' first commercial product, a cell-free, off-the-shelf hydrogel implant for treating painful injuries to articular knee cartilage. It is injected as a liquid, conforms to the lesion, and becomes a semisolid implant after UV light exposure, acting as a scaffold that gradually erodes as new cartilage replaces it.

When did Regentis Biomaterials become a publicly listed company?

Regentis Biomaterials became publicly listed on NASDAQ in September 2025.

What significant manufacturing advancement did Regentis Biomaterials announce in March 2026?

In March 2026, Regentis Biomaterials developed and patented a new solvent-free manufacturing process that increases GelrinC production yield by 400%.

What recent strategic move did Regentis Biomaterials make regarding its European commercial launch?

In June 2026, Regentis Biomaterials announced it would commence European surgeon training for GelrinC in knee cartilage repair, accelerating its commercial launch preparations in the region.